PURE Bioscience Announces Licensing and Distribution Agreement with Swabplus, Inc. for Distribution of SDC-based Disinfectant in China, Hong Kong and Taiwan

SAN DIEGO, CA August 9, 2007—PURE Bioscience (OTCBB: PURE) today announced it has granted a license to market and sell its patented silver dihydrogen citrate (SDC)-based hard surface disinfectant in China, Hong Kong and Taiwan to privately held Swabplus, Inc.

Under the terms of the Supply, Distribution and License Agreement, PURE will sell SDC concentrate to Swabplus for blending, packaging, and distribution of the SDC-based disinfectant product.  Swabplus has dedicated approximately 70,000 square feet of its 300,000 square foot state-of-the-art manufacturing facility in San Dong Province in China to the blending and packaging of SDC-based disinfectant.  In addition, Swabplus will assume compliance responsibility for all regulatory and legal requirements by national, state and local governments.  Specific financial terms of the contract were not disclosed.

Garry Tsaur, President of Swabplus, stated, “We are excited about the opportunity to introduce SDC into Asia as a more effective alternative to traditional poisonous disinfectants and a powerful weapon against dangerous pathogens including avian flu, SARS, MRSA and norovirus or norwalk virus.  The 24-hour residual protection against bacteria further differentiates the SDC-based disinfectant from competitors.  Asia’s cities are expanding at a tremendous rate, and the SDC-based disinfectant is a needed solution for infectious disease control in more densely populated areas.  Sales channels for the SDC-based disinfectant are the same as those for our current product offerings, and we look forward to establishing a market presence for this revolutionary product in the consumer and commercial arenas throughout Asia.”

Michael L. Krall, President and CEO commented, “Swabplus has been an investor in PURE for many years, and we are pleased to expand the relationship to include distribution of an SDC-based disinfectant in Asia.  Mr. Tsaur and his partners have demonstrated excellent business and government connections in Asia, and after visiting the plant in China, I am impressed with the quality and sophistication of Swabplus’ facilities in both the US and abroad.  Our agreement provides for increasing minimum purchases beginning in 2008 and we expect to begin filling initial orders for Swabplus by the end of 2007.”

About Swabplus

Swabplus, Inc., an international manufacturing, sales and marketing firm based in Rancho Cucamonga, California, designs, develops and manufactures a unique delivery system: small tubular devices containing liquids for medical, veterinary, cosmetic, health and beauty aid applications.  Swabplus’ current offerings include products in First Aid, Beauty Care, Oral Care, Foot Care and Pet Care categories, available at retail outlets nationally. Swabplus also partners with other manufacturers to offer its unique delivery system for their products, building awareness, market share and sales.  The Liquid Filled Swabs, release system (Liquid Switch) and manufacturing processes are patented.  Swabplus is registered as a drug establishment with the FDA and operates under a drug manufacturing license from the State of California Food and Drug Branch of the Department of Health Services, and is GMP compliant.  Swabplus also has manufacturing facilities in China and Taiwan.  For more information on Swabplus, please visit www.swabplus.com.

About PURE Bioscience

PURE Bioscience (PURE) develops and markets technology-based bioscience products that provide solutions to numerous global health challenges. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety.  Patented silver dihydrogen citrate (SDC) is an electrolytically generated source of stabilized ionic silver.  SDC is colorless, odorless, tasteless, non-toxic, non-caustic and formulates well with other compounds.  As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it.  SDC also offers 24-hour residual protection against standard indicator bacteria.  PURE Bioscience, headquartered in El Cajon, California (San Diego metropolitan area), was incorporated in 1992.  Additional information on PURE Bioscience is available at www.purebio.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

# # #